Treatment optimization: An outline for future success

Current Opinion in HIV and AIDS

Volumn 8, Issue 6, 2013, Pages 523-527

  Flexner, Charles ^a   Plumley, Ben ^b   Brown Ripin, David H ^c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Pangaea Global AIDS Foundation   (United States)

^c CLINTON HEALTH ACCESS INITIATIVE   (United States)

Author keywords

antiretroviral therapy; Conference on Antiretroviral Drug Optimization; fixed dose combinations; regimen simplification; universal access

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; COBICISTAT; DARUNAVIR; DOLUTEGRAVIR; EFAVIRENZ; EMTRICITABINE; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; LAMIVUDINE; RALTEGRAVIR; RIFAMPICIN; RITONAVIR; TENOFOVIR; TENOFOVIR ALAFENAMIDE; TENOFOVIR DISOPROXIL;

ABSENCE OF SIDE EFFECTS; ANTIVIRAL THERAPY; CARDIOVASCULAR DISEASE; COMORBIDITY; CONCURRENT INFECTION; DIABETES MELLITUS; DRUG BIOAVAILABILITY; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; HEPATITIS B; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; LOW DRUG DOSE; MEDICATION COMPLIANCE; MIXED INFECTION; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RECURRENT INFECTION; REVIEW; RISK REDUCTION; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; HIV INFECTIONS; HUMANS; MEDICATION ADHERENCE;

EID: 84886101679     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0000000000000003     Document Type: Review

References (13)

1. Duncombe C, Ball A, Passarelli C, Hirnschall G. Treatment 2.0: catalyzing the next phase of treatment, care and support. Curr Opin HIV AIDS 2013; 8:4-11.
2. Flexner C. HIV drug development: the next 25 years. Nat Rev Drug Disc 2007; 6:959-966.
3. Genberg BL, Wilson IB, Bangsberg DR, et al. MACH14 Investigators. Patterns of antiretroviral therapy adherence and impact on HIV RNA among patients in North America. AIDS 2012; 26:1415-1423.
4. World Health Organization Adult Guideline Development Group. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. Geneva: World Health Organization; 2013.
5. Crawford KW, Ripin DH, Levin AD, et al. Optimising the manufacture, formulation, and dose of antiretroviral drugs for more cost-efficient delivery in resource-limited settings: a consensus statement. Lancet Infect Dis 2012; 12:550-560.
6. Else LJ, Jackson A, Puls R, et al. Pharmacokinetics of lamivudine and lamivudine-triphosphate after administration of 300 milligrams and 150 milligrams once daily to healthy volunteers: results of the ENCORE 2 study. Antimicrob Agents Chemother 2012; 56:1427-1433.
7. Stellbrink HJ, Reynes J, Lazzarin A, et al. Dolutegravir in antiretroviral-naive adults with HIV-1: 96-week results from a randomized dose-ranging study. AIDS 2013; 27:1771-1778.
8. Dooley KE, Sayre P, Borland J, et al. Safety, tolerability, and pharmacokinetics of the HIV integrase inhibitor dolutegravir given twice daily with rifampin or once daily with rifabutin: results of a phase 1 study among healthy subjects. J Acquir Immune Defic Syndr 2013; 62:21-27.
9. Ruane PJ, Dejesus E, Berger D, et al. Antiviral activity, safety, and pharmacokinetics/ pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adults. J Acquir Immune Defic Syndr 2013; 63:449-455.
10. Robertson J, Feinberg J. Darunavir: a nonpeptidic protease inhibitor for antiretroviral-naive and treatment-experienced adults with HIV infection. Expert Opin Pharmacother 2012; 13:1363-1375.
11. Cohen MS, Chen YQ, McCauley M, et al. HPTN 052 Study Team. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011; 365:493-505.
12. Padian NS, McCoy SI, Karim SS, et al. HIV prevention transformed: the new prevention research agenda. Lancet 2011; 378:269-278.
13. Tanser F, Bärnighausen T, Grapsa E, et al. High coverage of ART associated with decline in risk of HIV acquisition in rural KwaZulu-Natal, South Africa. Science 2013; 339:966-971.